Plasmid-encoded NP73-102 modulates atrial natriuretic peptide receptor signaling and plays a critical role in inducing tolerogenic dendritic cells
- Weidong Zhang†1,
- Xueqin Cao†2,
- Dongqing Chen1,
- Jia-wang Wang3,
- Hong Yang4,
- Wenshi Wang5,
- Subhra Mohapatra2, 6,
- Gary Hellermann1,
- Xiaoyuan Kong1,
- Richard F Lockey1, 3 and
- Shyam S Mohapatra1, 3, 6Email author
© Zhang et al; licensee BioMed Central Ltd. 2011
Received: 23 April 2010
Accepted: 10 January 2011
Published: 10 January 2011
Atrial natriuretic peptide (ANP) is an important endogenous hormone that controls inflammation and immunity by acting on dendritic cells (DCs); however, the mechanism remains unclear.
We analyzed the downstream signaling events resulting from the binding of ANP to its receptor, NPRA, and sought to determine what aspects of this signaling modulate DC function.
We utilized the inhibitory peptide, NP73-102, to block NPRA signaling in human monocyte-derived DCs (hmDCs) and examined the effect on DC maturation and induced immune responses. The potential downstream molecules and interactions among these molecules involved in NPRA signaling were identified by immunoprecipitation and immunoblotting. Changes in T cell phenotype and function were determined by flow cytometry and BrdU proliferation ELISA. To determine if adoptively transferred DCs could alter the in vivo immune response, bone marrow-derived DCs from wild-type C57BL/6 mice were incubated with ovalbumin (OVA) and injected i.v. into C57BL/6 NPRA-/- knockout mice sensitized and challenged with OVA. Lung sections were stained and examined for inflammation and cytokines were measured in bronchoalveolar lavage fluid collected from parallel groups of mice.
Inhibition of NPRA signaling in DCs primes them to induce regulatory T cells. Adoptive transfer of wild type DCs into NPRA-/- mice reverses the attenuation of lung inflammation seen in the NPRA-knockout model. NPRA is associated with TLR-2, SOCS3 and STAT3, and inhibiting NPRA alters expression of IL-6, IL-10 and TGF-β, but not IL-12.
Modulation of NPRA signaling in DCs leads to immune tolerance and TLR2 and SOCS3 are involved in this induction.
Allergic asthma is a chronic inflammatory disease of the lung, involving an aberrant T helper-2 (Th2) immune response to allergens. The etiology of asthma is complex and involves a number of signaling molecules and pathways as well as environmental factors. Atrial natriuretic peptide (ANP) is a cardiac hormone that regulates blood pressure and volume and the sodium/potassium balance. Atrial natriuretic factor is synthesized as a prohormone that is cleaved into a C-terminal peptide, ANP, and a group of three N-terminal peptides which are released into the circulation and may negatively inhibit ANP activity. ANP binds to a cell surface receptor, natriuretic peptide receptor A (NPRA), which is found on cells in the lung and airways as well as kidney and other tissues. Hormone binding to NPRA is the predominant trigger in the natriuretic system and generates the intracellular signaling molecule cyclic guanosine monophosphate (cGMP) which can activate cGMP-dependent protein kinase and initiate a cascade of events. Patients with asthma or inflammatory lung disease have elevated levels of circulating ANP , which suggests that manipulation of NPRA signaling might provide a therapeutic benefit for asthmatics .
The natriuretic peptide family comprises atrial natriuretic peptide, ANP, brain natriuretic peptide, BNP, C-type natriuretic peptide, CNP, Dendroaspis natriuretic peptide, DNP, and urodilatin . The activities of ANP and BNP are similar, and their biological actions, such as vasodilation and natriuresis, are mediated through binding to their receptor, NPRA, which leads to production of the intracellular second messenger cGMP . Besides expression in heart atria, ANP is also produced in various lymphoid organs , and the NPRA receptor is found on immune cells of numerous species highlighting the importance of NPRA signaling in the immune response .
Over-production of ANP can affect the adaptive immune system by altering dendritic cell (DC) differentiation and promoting a Th2 response characteristic of allergic disease . However, the mechanism by which NPRA signaling in DCs alters the innate and adaptive immune responses is unclear. In animal models of allergic lung inflammation, we showed that ANP signaling through NPRA promotes lung histopathology . In studying the regulation of NPRA, we discovered a peptide, NP73-102, from the N-terminus of the ANP prohormone that acts as a brake on ANP signaling by reducing expression of NPRA. NP73-102 consists of amino acids 73 to 102 of the ANP prohormone and has bronchoprotective effects in a mouse model of asthma and anti-inflammatory activity in human epithelial cells . The amino acid sequence of this peptide is different from ANP and NP73-102 does not bind to NPRA and prevent ANP from attaching. NP73-102 reduces ANP-induced signaling by downregulating its receptor and by feedback inhibition of ANP production .
DCs express abundant NPRA while macrophages do not. It was therefore hypothesized that the effects of NPRA signaling on innate and adaptive immunity occur through NPRA-mediated alterations in gene expression in DCs. Little is known about the role of NPRA signaling in innate immunity and about the downstream effects of NPRA-mediated immunoregulation in DCs. Tolerogenic DCs present antigen to T cells, but do not deliver the signals for effector T-cell activation and proliferation. This lack of costimulation can result in T-cell apoptosis , T-cell anergy  or differentiation into regulatory T-cells (Tregs) . The identification of ANP's effects on DCs as key regulators of peripheral tolerance to allergens may be important in the prevention and treatment of allergic diseases [14, 15].
In this study, the NPRA inhibitory peptide NP73-102 was utilized to block NPRA signaling in human DCs and to analyze the downstream cascade events. The results demonstrate that Toll-like receptor-2 (TLR2) and suppressor of cytokine synthesis-3 (SOCS3) are key players in integrating NPRA signaling with innate immunity and in the induction of tolerogenic DCs.
Materials and methods
Isolation, transfection and viability assay of human dendritic cells
Human monocytes were isolated from peripheral blood mononuclear cells using the Monocyte Isolation Kit II (Miltenyi Biotec, Auburn, CA). Human monocyte-derived DCs (HmDCs) were generated from these cells as previously described . Briefly, monocytes isolated from peripheral blood mononuclear cells were induced to differentiate into DCs by incubation with 200 ng/ml IL-4 and 50 ng/ml GM-CSF. Five day-old DCs were transfected with the indicated plasmid (3 μg/106 cells) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After 24 hr, cell viability was measured by MTT assay (Sigma/Aldrich, St Louis, MO). Additional information on the viability assay is provided in Additional File 1.
Transfected hmDCs (1 × 106 cells/well) were cultured in 24-well plates for 24 h. Cytokine levels in the cell-culture supernatants were measured using a cytokine bead array kit (BioSystem, Bio-Rad) following the manufacturer's directions. All samples were assayed in duplicate.
Isolation of naïve T cells, generation of Tregs and T-cell suppression assay
Human allogeneic naïve CD4+CD25-T cells were purified from umbilical cord blood using the naïve T cell isolation kit with biotinylated CD25 antibody (Miltenyi Biotec, Auburn, CA) and co-cultured with irradiated transfected hmDCs (10:1 ratio) in 24-well plates for 6 days. Expression of the Treg protein FoxP3 by co-cultured T cells was quantitated by flow cytometry (BD-FACScan, BD Biosciences, San Jose, CA). Also, total RNA was extracted and analyzed by reverse transcriptase-PCR for FoxP3. Tregs were purified with the Treg cell isolation kit (Miltenyi Biotec.) and a co-culture suppression assay was performed using a BrdU proliferation ELISA kit (Roche, IN, USA) as previously described . Additional information is provided in the Additional File.
Measurement of intracellular cGMP
Five day-old hmDCs (106 cells/sample) were transfected with the indicated plasmid and incubated in medium for 18 h. After incubation, the cells were removed from the plate, pelleted by centrifugation (750× g, 5 min) and intracellular cGMP in the cell pellets was measured with a cGMP ELISA kit (R & D Systems, Minneapolis, MN).
Five day-old hmDCs (106) were harvested 24 hr post-transfection and resuspended in RPMI 1640 medium supplemented with 2% FBS. The FITC-dextran phagocytosis assay was performed as described .
Immunoprecipitation and immunoblotting
Five day-old hmDCs were transfected with 3 μg each of expression plasmid encoding NPRA, TLR2, STAT3 and SOCS3 and then harvested 24 hr post-transfection. Lysates (400 μg of protein/sample) were immunoprecipitated with antibody against TLR2, STAT3, SOCS3 or NPRA overnight at 4°C. The antibody complexes were precipitated by the addition of recombinant protein G agarose (Invitrogen, Carlsbad, CA). Eluted proteins were resolved on 12% SDS-PAGE gels, transferred to PVDF membranes (Bio-Rad, Hercules, CA) and immunoblotted with the indicated antibodies.
HmDCs were transfected with the indicated plasmid and 48 h later, the cells were analyzed for luciferase activity. Additional detail is provided in the Additional File.
Studies in mice: OVA sensitization, DC isolation and adoptive transfer
Bone marrow cells were removed from C57BL/6 NPRA-/- or wild type (WT) mice and cultured for 8 days as described previously . Bone marrow-derived DCs (bmDCs) were purified using CD11c microbeads (Miltenyi Biotec, Auburn, CA), incubated with ovalbumin (OVA; 0.5 mg/ml) for 24 hr and injected i.v. into NPRA-/- mice (5 × 106 bmDCs/mouse), which had been sensitized (i.p) and challenged (i.n) with OVA (25 μg). Mice were euthanatized, lungs were lavaged with 1 ml of PBS, and BAL cytokines were quantitated by cytokine bead array (BioSystem, Bio-Rad, Hercules, CA). Lung histopathology was assessed using a previously described scoring system . Additional details are provided in the Additional File.
The results are expressed as means ± SEM. Data were analyzed using an unpaired two-tailed Student's t test.
NP73-102 inhibits NPRA signaling in human DCs
Inhibiting NPRA signaling alters cytokine production in human DCs
Inhibiting NPRA signaling in human DCs induces Tregs
Inhibiting NPRA signaling does not affect maturation of human DCs
The degree of hmDC maturation affects their capacity for Treg generation, and therefore the NPRA signal blockade was investigated to see if it alters hmDC maturation. Using the ability to phagocytose as a measure of maturation, pVAX or mock transfection slightly lowered hmDC phagocytosis compared to pNP73-102 or pANP (Figure 3D). Further, the hmDC phenotype analysis showed that HLA-DR, CD11c, CD40 and CD80 did not significantly change in expression among the groups (Figure 3E), suggesting that NPRA signaling does not affect hmDC maturation.
NPRA inhibition alters expression of TLR-2, STAT3 and SOCS3 in human DCs
Protein interactions in the NPRA signal pathway
Adoptively transferred wild type mouse bone marrow-derived DCs (bmDCs) restore lung inflammation in NPRA-/- mice
A novel mechanism for inducing tolerogenic DCs by inhibition of NPRA signaling in DCs is described. Our demonstration that down-regulation of NPRA levels and reduction in NPRA signaling in DCs increases the population of Tregs may have important applications in treating respiratory disease and inflammatory conditions. Effective allergen immunotherapy involves generation of Treg cells, and targeted NPRA down-regulation may be used as a means to develop tolerogenic DCs that induce Tregs to ameliorate or prevent inflammation.
The discovery of the NPRA inhibitory peptide NP73-102, which reduces expression of NPRA and inhibits NPRA signaling and the activation of several pro-inflammatory transcription factors in epithelial cells [8, 9], has provided the impetus to study the mechanism of how NPRA signaling affects inflammation and immunity. Increased NPRA signaling in DCs leads to a Th2 response, which restricts Treg production, while inhibiting signaling induces more IL-10 and TGF-β production and stimulates Treg formation.
Using an in vitro T cell-DC coculture system, down-regulation of NPRA by NP73-102 resulted in greater DC-mediated generation of Tregs. Analysis of DC surface marker expression and in vitro phagocytosis demonstrated that DC maturation was not significantly affected by NPRA signaling blockade. The mechanism underlying the NP73-102-induced Treg response is not fully understood. It may be due to inactivation of NF-κB activity by NP73-102 inhibition of NPRA signaling, since inhibition of NF-κB in DCs enhances their tolerogenic activity and prevents detrimental autoimmune diseases .
These data demonstrate that pNP73-102 increases the level of IL-10 and TGF-β, but not of IL-12 and IFN-γ, compared to cells given pANP or vector alone. TGF-β, which inhibits Th1 and Th2 development, is critical in Th17 development, in combination with IL-6  and leads to the generation of Foxp3-positive regulatory T cells . However, there was no increase in the number of Th17 lymphocytes, even in the presence of IL-6, in the DC-naïve T cell co-culture system, suggesting that Tregs may inhibit Th17 generation or that different cytokine profiles may produce diverse outcomes . As shown in Figure 3A, the pANP-treated group also induced few Tregs versus the empty vector control, suggesting that TGF-β may be involved in the process (Figure 2E &2F). However, attenuation of NPRA signaling by pNP73-102 induced a greater amount of SOCS3 and generated more Tregs which supports the hypothesis that ANP signaling effects are mediated through production of tolerogenic DCs. Data show that ANP inhibits TGF-β-induced Smad2 and Smad3 nuclear translocation in rat pulmonary arterial smooth muscle cells , which is consistent with our finding that ANP induced less TGF-β production in human DCs than NP73-102.
The SOCS3 protein was strongly induced by both IL-6 and IL-10. SOCS3 selectively inhibits IL-6 signaling via its binding to the IL-6 receptor, but does not inhibit the IL-10 receptor . The suppressive effect of SOCS3 is primarily restricted to STAT3 , and these results show that pNP73-102 inhibits STAT3 activity and enhances SOCS3 expression. This is in marked contrast to pANP and the vector control, which induce STAT3 phosphorylation and decrease SOCS3 expression in hmDCs. These data further support the idea that in this model, NPRA signaling in tolerogenic DCs involves the regulation of SOCS3 expression and STAT3 activity.
Cells exposed to pNP73-102 selectively diminished TLR2 expression compared to cells given pANP or vector. This could be explained by decreased NF-κB-mediated down-regulation of TLR through a binding site for NF-κB on the TLR2 promoter . Reports have indicated that down-regulation of both TLR4 and TLR2 expression in mice decreases the expression of inflammatory cytokines and enhances production of anti-inflammatory cytokines, which induce immune tolerance . Significantly, enhanced MyD88 expression was found in DCs treated with pNP73-102 compared to pANP and vector control. An LPS-inducible MyD88 is defective in its ability to induce IRAK phosphorylation and behaves as a dominant-negative inhibitor of LPS-induced NF-κB activation . Also, MyD88-knockout mice show significantly reduced expression of SOCS3 , which is in part consistent with our data, although it is unclear why pANP induced higher SOCS3 expression in the absence of MyD88 than vector control. Thus, the enhanced expression of both SOCS3 and MyD88 in DCs may be associated with a reduced response to ANP, whereas the specific enhancement of SOCS3 and/or MyD88 expression may explain the generation of tolerogenic DCs.
Indirect inhibition of JAKs due to the binding of SOCS to membrane proximal regions of receptor chains results in steric hindrance of constitutive JAK binding to the receptor . Inhibition of NPRA signaling by pNP73-102 through SOCS3 might occur by this mechanism. The IP data support this hypothesis. NPRA binds to SOCS3, and this interaction might contribute to the effects of NPRA signaling on immunoregulation. NPRA also binds to TLR2 and STAT3. However, TLR2 and SOCS3 involvement in regulation of NPRA expression (unpublished data) might result from these protein interactions rather than STAT3 involvement. Further work is needed to clarify whether the interactions among these proteins are direct or indirect.
In our animal model, we found that NPRA-/- mice had decreased expression of Th2-like cytokines, and that adoptive transfer of DCs from WT to NPRA-/- mice restored levels of these cytokines to those seen in WT. This is an important finding since it complements the in vitro results in an animal model. The lungs from NPRA-/- mice given DCs from WT mice exhibited inflammation similar to that of the WT. OVA-treated NPRA-/- mice given no DCs or given DCs from NPRA-/- mice did not have significant lung inflammation (Figure 6A, B), suggesting that DCs are the key mediators in modulating lung inflammation by NPRA signaling.
Taken together, our results demonstrate a novel mechanism for integration of TLR2, STAT3 and SOCS3 with NPRA signaling to regulate the immunomodulatory activity of DCs. They support the hypothesis that inhibition of NPRA signaling and TLR2 expression in DCs induces more IL-10 and TGF-β secretion and increases SOCS3 expression, thereby promoting the generation of Treg cells.
SSM is supported by grants from the Veterans' Affairs Merit Review Award and U.S. National Institutes of Health #5RO1HL71101-01A2. We thank Dr. Hirohide Yoshikawa (JFCR Cancer Institute, Japan) for his pSOCS3 constructs, Drs. G. J. Rosman and D. A. Miller (Biotechniques, Germany) for their gift of pSTAT3-YFP, Dr. Toshio Hirano (Osaka University, Japan) for the plasmid pSTAT3-luc, Dr. W. R. Gower, Jr. (University of South Florida, USA) for the plasmid, pNPRA, and Dr. Weidong Xu (University of South Florida, USA) for the plasmids, pANP and pNP73-102. We would also like to express our appreciation to Saneron-Cell Therapeutics (Tampa, Florida, USA) for the cord blood cells and to the Moffitt Flow Cytometry and Microscopy Core for their assistance.
- Passino C, Poletti R, Fontana M, Vergaro G, Prontera C, Gabutti A: Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clin Chem Lab Med. 2008, 46: 1515-23. 10.1515/CCLM.2008.293.View ArticlePubMed
- Mohapatra SS: Role of natriuretic peptide signaling in modulating asthma and inflammation. Can Physiol Pharmacol. 2007, 85: 754-9. 10.1139/Y07-066.View Article
- Piechota M, Banach M, Jacon A, Rysz J: Natriuretic peptides in cardiovascular diseases. Cell Mol Biol Lett. 2008, 13: 155-81. 10.2478/s11658-007-0046-6.View ArticlePubMed
- Pandey KN: Internalization and trafficking of guanylyl cyclase/natriuretic peptide receptor-A. Peptide. 2005, 26: 985-1000. 10.1016/j.peptides.2004.12.020.View Article
- Gutkowska J, Nemer M: Structure, expression and function of atrial natriuretic factor in extraatrial tissues. Endocrinol Rev. 1989, 10: 519-37. 10.1210/edrv-10-4-519.View Article
- Kiemer AK, Vollmar AM: Effects of different natriuretic peptides on nitric oxide synthesis in macrophages. Endocrinology. 1997, 138: 4282-90. 10.1210/en.138.10.4282.PubMed
- Morita R, Ukyo N, Furuya M, Uchiyama T, Hori T: Atrial natriuretic peptide polarizes human dendritic cells toward a Th2-promoting phenotype through its receptor guanylyl cyclase-coupled receptor A. J Immunol. 2003, 15: 5869-75.View Article
- Wang X, Xu W, Mohapatra S, Kong X, Li X, Lockey RF: Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor. Genet Vaccines Ther. 2008, 15: 6-7.
- Kumar M, Kong X, Behera AK, Hellermann GR, Lockey RF, Mohapatra SS: Chitosan IFN-gamma-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma. Genet Vaccines Ther. 2003, 27: 1-3.
- Mohapatra SS, Lockey RF, Vesely DL, Gower WR: Natriuretic peptides and genesis of asthma: an emerging paradigm?. J Allergy Clin Immunol. 2004, 114: 520-26. 10.1016/j.jaci.2004.05.028.View ArticlePubMed
- Suss G, Shortman K: A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med. 1996, 183: 1789-96. 10.1084/jem.183.4.1789.View ArticlePubMed
- Zheng Z, Narita M, Takahashi M, Liu A, Furukawa T, Toba K: Induction of T cell anergy by the treatment with IL-10-treated dendritic cells. Comp Immunol Microbiol Infect Dis. 2004, 27: 93-103. 10.1016/S0147-9571(03)00054-7.View ArticlePubMed
- Jonuleit H, Adema G, Schmitt E: Immune regulation by regulatory T cells: implications for transplantation. Transpl Immunol. 2003, 11: 267-76. 10.1016/S0966-3274(03)00057-1.View ArticlePubMed
- Akdis CA, Akdis M: Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol. 2009, 123: 735-46. 10.1016/j.jaci.2009.02.030.View ArticlePubMed
- Henry E, Desmet CJ, Garze V, Fievez L, Bedoret D, Heirman C: Dendritic cells genetically engineered to express IL-10 induce long-lasting antigen-specific tolerance in experimental asthma. J Immunol. 2008, 181: 7230-42.View ArticlePubMed
- Zhang W, Yang H, Kong X, Mohapatra S, San Juan-Vergara H, Hellermann G: Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med. 2005, 11: 56-62. 10.1038/nm1174.View ArticlePubMed
- Zhao X, Ye F, Chen L, Lu W, Xie X: Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4+CD25-CD45RA+ naïve T cells to express forkhead box protein 3 and exhibit suppressive ability in vitro. Cancer Sci. 2009, 100: 2143-51. 10.1111/j.1349-7006.2009.01286.x.View ArticlePubMed
- Liu Y, Zhang W, Chan T, Saxena A, Xiang J: Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk Res. 2002, 26: 757-63. 10.1016/S0145-2126(02)00002-4.View ArticlePubMed
- Zhang W, Chen Z, Li F, Kamencic H, Juurlink B, Gordon JR: Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha. Immunology. 2003, 108: 177-88. 10.1046/j.1365-2567.2003.01489.x.PubMed CentralView ArticlePubMed
- Sommer K, Njau F, Wittkop U, Thalmann J, Bartling G, Wagner A: Identification of high- and low-virulent strains of Chlamydia pneumoniae by their characterization in a mouse pneumonia model. FEMS Immunol Med Microbiol. 2009, 55: 206-14. 10.1111/j.1574-695X.2008.00503.x.View ArticlePubMed
- Dalpke AH, Eckerle S, Frey M, Heeg K: Triggering of Toll-like receptors modulates IFN-gamma signaling: involvement of serine 727 STAT1 phosphorylation and suppressors of cytokine signaling. Eur J Immunol. 2003, 33: 1776-87. 10.1002/eji.200323621.View ArticlePubMed
- Iruretagoyena MI, Sepulveda SE, Lezana JP, Hermoso M, Bronfman M, Gutierrez MA: Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther. 2006, 318: 59-67. 10.1124/jpet.106.103259.View ArticlePubMed
- Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006, 441: 235-38. 10.1038/nature04753.View ArticlePubMed
- Toh ML, Miossec P: The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol. 2007, 19: 284-88. 10.1097/BOR.0b013e32805e87e0.View ArticlePubMed
- Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD: TGF-β-induced Foxp3 inhibits Th17 cell differentiation by antagonizing RORγt function. Nature. 2008, 453: 236-40. 10.1038/nature06878.PubMed CentralView ArticlePubMed
- Li P, Oparil S, Novak L, Cao X, Shi W, Lucas J: ANP signaling inhibits TGF-β-induced Smad2 and Smad3 unclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells. J Appl Physiol. 2007, 102: 390-98. 10.1152/japplphysiol.00468.2006.View ArticlePubMed
- Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D: IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol. 2003, 4: 551-56. 10.1038/ni938.View ArticlePubMed
- Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Biorbaek C, Flier JS: Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med. 2004, 10: 734-38. 10.1038/nm1072.View ArticlePubMed
- Musikacharoen T, Matsuguchi T, Kikuchi T, Yoshikai Y: NF-κB and STAT5 play important roles in the regulation of mouse Toll-like receptor 2 gene expressions. J Immunol. 2001, 166: 4516-24.View ArticlePubMed
- Eguchi M, Sekiya Y, Suzuki M, Yamamoto T, Matsui H: An oral salmonella vaccine promotes the down-regulation of cell surface Toll-like receptor 4 (TLR4) and TLR2 expression in mice. FEMS Immunol Med Microbiol. 2007, 50: 300-8. 10.1111/j.1574-695X.2007.00240.x.View ArticlePubMed
- Janssens S, Burns K, Tschopp J, Beyaert R: Regulation of interleukin-1- and lipopolysaccharide-induced NF-kappaB activation by alternative splicing of MyD88. Curr Biol. 2002, 12: 467-71. 10.1016/S0960-9822(02)00712-1.View ArticlePubMed
- Campbell JS, Riehle KJ, Brooling JT, Bauer RL, Mitchell C, Fausto N: Proinflammatory cytokine production in liver regeneration is MyD88-dependent, but independent of Cd14, Tlr2, and Tlr4. J Immunol. 2006, 176: 2522-28.View ArticlePubMed
- Ilangumaran S, Ramanathan S, Rottapel R: Regulation of the immune system by SOCS family adaptor proteins. Seminars Immunol. 2004, 16: 351-65. 10.1016/j.smim.2004.08.015.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.